Tags

Type your tag names separated by a space and hit enter

Alterations in hormonal receptor expression and HER2 status between primary breast tumors and paired nodal metastases: discordance rates and prognosis.
Asian Pac J Cancer Prev. 2014; 15(21):9233-9.AP

Abstract

BACKGROUND

We aimed to evaluate the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression discordance in matched pairs of primary breast cancer and lymph node metastasis specimens and determine the effect of discordance on prognosis.

MATERIALS AND METHODS

Among all patients diagnosed with lymph node metastases from 2004 to 2007, primary tumors and paired lymph node metastases were resected from 209 patients. The status of ER, PR, and HER2 expression was analyzed immunohistochemically in 200, 194, and 193 patients, respectively. Discordance was correlated with prognosis.

RESULTS

Biomarker discordance between primary tumors and paired lymph node metastases was 25.0% (50/200) for ER status, 28.9% (56/194) for PR status, and 14.0% (27/193) for HER2 status. ER positivity was a significant independent predictor of improved survival when analyzed in primary tumors and lymph node metastases. Patients with PR-positive primary tumors and paired lymph node metastases displayed significantly enhanced survival compared to patients with PR-positive primary tumors and PR-negative lymph node metastases. Patients with ER- and PR-positive primary tumors and paired lymph node metastases who received endocrine therapy after surgery displayed significantly better survival than those not receiving endocrine therapy. Similalry treated patients with PR-negative primary tumors and PR-positive paired lymph node metastases also displayed better survival than those not receiving endocrine therapy.

CONCLUSIONS

Biomarker discordance was observed in matched pairs of primary tumors and lymph node metastases. Such cases displayed poor survival. Thus, it is important to reassess receptor biomarkers used for lymph node metastases.

Authors+Show Affiliations

Department of Breast Surgery, General Surgery, the First Hospital of China Medical University, Liaoning Province, China E-mail : jinfeng66cn@hotmail.com, bajinlingno12@126.com.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

25422206

Citation

Ba, Jin-Ling, et al. "Alterations in Hormonal Receptor Expression and HER2 Status Between Primary Breast Tumors and Paired Nodal Metastases: Discordance Rates and Prognosis." Asian Pacific Journal of Cancer Prevention : APJCP, vol. 15, no. 21, 2014, pp. 9233-9.
Ba JL, Liu CG, Jin F. Alterations in hormonal receptor expression and HER2 status between primary breast tumors and paired nodal metastases: discordance rates and prognosis. Asian Pac J Cancer Prev. 2014;15(21):9233-9.
Ba, J. L., Liu, C. G., & Jin, F. (2014). Alterations in hormonal receptor expression and HER2 status between primary breast tumors and paired nodal metastases: discordance rates and prognosis. Asian Pacific Journal of Cancer Prevention : APJCP, 15(21), 9233-9.
Ba JL, Liu CG, Jin F. Alterations in Hormonal Receptor Expression and HER2 Status Between Primary Breast Tumors and Paired Nodal Metastases: Discordance Rates and Prognosis. Asian Pac J Cancer Prev. 2014;15(21):9233-9. PubMed PMID: 25422206.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Alterations in hormonal receptor expression and HER2 status between primary breast tumors and paired nodal metastases: discordance rates and prognosis. AU - Ba,Jin-Ling, AU - Liu,Cai-Gang, AU - Jin,Feng, PY - 2014/11/26/entrez PY - 2014/11/26/pubmed PY - 2015/7/16/medline SP - 9233 EP - 9 JF - Asian Pacific journal of cancer prevention : APJCP JO - Asian Pac J Cancer Prev VL - 15 IS - 21 N2 - BACKGROUND: We aimed to evaluate the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression discordance in matched pairs of primary breast cancer and lymph node metastasis specimens and determine the effect of discordance on prognosis. MATERIALS AND METHODS: Among all patients diagnosed with lymph node metastases from 2004 to 2007, primary tumors and paired lymph node metastases were resected from 209 patients. The status of ER, PR, and HER2 expression was analyzed immunohistochemically in 200, 194, and 193 patients, respectively. Discordance was correlated with prognosis. RESULTS: Biomarker discordance between primary tumors and paired lymph node metastases was 25.0% (50/200) for ER status, 28.9% (56/194) for PR status, and 14.0% (27/193) for HER2 status. ER positivity was a significant independent predictor of improved survival when analyzed in primary tumors and lymph node metastases. Patients with PR-positive primary tumors and paired lymph node metastases displayed significantly enhanced survival compared to patients with PR-positive primary tumors and PR-negative lymph node metastases. Patients with ER- and PR-positive primary tumors and paired lymph node metastases who received endocrine therapy after surgery displayed significantly better survival than those not receiving endocrine therapy. Similalry treated patients with PR-negative primary tumors and PR-positive paired lymph node metastases also displayed better survival than those not receiving endocrine therapy. CONCLUSIONS: Biomarker discordance was observed in matched pairs of primary tumors and lymph node metastases. Such cases displayed poor survival. Thus, it is important to reassess receptor biomarkers used for lymph node metastases. SN - 2476-762X UR - https://www.unboundmedicine.com/medline/citation/25422206/Alterations_in_hormonal_receptor_expression_and_HER2_status_between_primary_breast_tumors_and_paired_nodal_metastases:_discordance_rates_and_prognosis_ L2 - http://journal.waocp.org/?sid=Entrez:PubMed&id=pmid:25422206&key=2014.15.21.9233 DB - PRIME DP - Unbound Medicine ER -